Amidst growing enthusiasm for AI in healthcare, there are open questions on how we should pay for AI services.
In a new piece at @Health_Affairs we weigh in. https://t.co/oDButtmoc8
New 📰@AnnalsofIM
TLDR: We find the average older adult in traditional Medicare spends 3 weeks per year getting health care, mostly (17 days) ambulatory care like office visits, tests, and treatments.
11% of these adults spent 50+ days per year (!).
https://t.co/49Wq5lWo7U
We all know that fentanyl is making the overdose crisis much worse.
But did you know that it's also making buprenorphine — the most popular opioid addiction treatment — harder to use?
I dug into it for @tradeoffspod's first new episode of 2024.
https://t.co/f2PMbNzHqb
Everyone knows NP and PA’s are playing a bigger role in the medical system. But until this study, I didn’t realize how large a fraction of care they provide!
Telemedicine was a crucial stop-gap during the pandemic, but are its best days behind us? Or is there more potential to tap?
Excited to share a new article w/ @Ateevm & @bbrownretail examining the tech, processes, and institutions that can unlock the next chapter of virtual care
New in @JAMANetworkOpen: In nat'l Medicare survey, many older adults were personally offered phone visits, or chose phone visits, even when phone & video visits were available.
🧵on results, implications for Medicare/other payers' reimbursement policies
https://t.co/kYsV73CFgy
Rates of antibiotics received during #COVID-19 outpatient visits (mostly amoxicillin & azithromycin) varied by age, site, and region in this cross-sectional study. @martjm@ateevm @krayhsr https://t.co/zljes5NlQB
Excited to share a new paper today with @McGarryBE and @ashdgandhi published today in @NEJM
TL;DR Nursing homes with higher use of COVID-19 tests for staff had 30% fewer resident cases and 26% fewer deaths than low testing facilities. That's a LOT.
/1
https://t.co/FJkuPBxWv6
DEA just proposed new rules limiting prescribing of buprenorphine via telemedicine. In a letter to DEA, we summarize evidence on using telemedicine to treat opioid use disorder & why new rules are problematic. Couple of highlights in this thread (1/5)
https://t.co/QXVFMOpJtX
In summary, our argument is no compelling evidence that new restrictions are needed & may cut off many from a life-saving drug. We call for DEA to revisit the proposed rule. If you agree, consider posting a comment on the DEA website. (5/)
https://t.co/eWzmp90ThR